Barclays Raises IDEXX Laboratories (NASDAQ:IDXX) Price Target to $520.00

IDEXX Laboratories (NASDAQ:IDXX) had its target price hoisted by analysts at Barclays from $481.00 to $520.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 10.98% from the company’s previous close.

A number of other brokerages also recently commented on IDXX. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Piper Sandler restated a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Finally, Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $524.38.

IDEXX Laboratories Trading Up 0.8 %

NASDAQ IDXX opened at $468.55 on Tuesday. IDEXX Laboratories has a 52 week low of $398.50 and a 52 week high of $583.39. The firm has a 50 day moving average of $425.88 and a two-hundred day moving average of $453.51. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $38.37 billion, a PE ratio of 45.18, a price-to-earnings-growth ratio of 3.64 and a beta of 1.37.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IDXX. SRS Capital Advisors Inc. grew its position in IDEXX Laboratories by 363.3% in the 4th quarter. SRS Capital Advisors Inc. now owns 366 shares of the company’s stock valued at $151,000 after buying an additional 287 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of IDEXX Laboratories by 10.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 635 shares of the company’s stock worth $262,000 after acquiring an additional 58 shares during the period. Middleton & Co. Inc. MA boosted its holdings in shares of IDEXX Laboratories by 98.1% in the fourth quarter. Middleton & Co. Inc. MA now owns 12,305 shares of the company’s stock valued at $5,087,000 after acquiring an additional 6,095 shares in the last quarter. Metis Global Partners LLC increased its stake in shares of IDEXX Laboratories by 6.5% during the fourth quarter. Metis Global Partners LLC now owns 5,874 shares of the company’s stock worth $2,429,000 after acquiring an additional 359 shares during the period. Finally, SVB Wealth LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $999,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.